Treg gene signatures predict and measure type 1 diabetes trajectory.

JCI Insight 2019 03 21;4(6). Epub 2019 Mar 21.

Department of Surgery, University of British Columbia (UBC), and BC Children's Hospital Research Institute (BCCHRI), Vancouver, British Columbia, Canada.

Background: Multiple therapeutic strategies to restore immune regulation and slow type 1 diabetes (T1D) progression are in development and testing. A major challenge has been defining biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or measure intervention effects. We previously found that, compared with healthy controls, Tregs from children with new-onset T1D have an altered Treg gene signature (TGS), suggesting that this could be an immunoregulatory biomarker.

Methods: nanoString was used to assess the TGS in sorted Tregs (CD4+CD25hiCD127lo) or peripheral blood mononuclear cells (PBMCs) from individuals with T1D or type 2 diabetes, healthy controls, or T1D recipients of immunotherapy. Biomarker discovery pipelines were developed and applied to various sample group comparisons.

Results: Compared with controls, the TGS in isolated Tregs or PBMCs was altered in adult new-onset and cross-sectional T1D cohorts, with sensitivity or specificity of biomarkers increased by including T1D-associated SNPs in algorithms. The TGS was distinct in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow C-peptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (αIL-12/23p40) for future rapid versus slow C-peptide decline.

Conclusion: These data suggest that biomarkers based on measuring TGSs could be a new approach to stratify patients and monitor autoimmune activity in T1D.

Funding: JDRF (1-PNF-2015-113-Q-R, 2-PAR-2015-123-Q-R, 3-SRA-2016-209-Q-R, 3-PDF-2014-217-A-N), the JDRF Canadian Clinical Trials Network, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1AI109565 and FY15ITN168), and BCCHRI.

Download full-text PDF

Source
http://insight.jci.org/articles/view/123879
Publisher Site
http://dx.doi.org/10.1172/jci.insight.123879DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483004PMC
March 2019
39 Reads

Publication Analysis

Top Keywords

type diabetes
16
healthy controls
8
future rapid
8
rapid versus
8
slow c-peptide
8
versus slow
8
treg gene
8
t1d
7
tgs
5
t1d versus
4
versus type
4
tgs distinct
4
distinct t1d
4
t1d-associated snps
4
increased including
4
including t1d-associated
4
diabetes indicating
4
snps algorithms
4
algorithms tgs
4
tgs measurement
4

Similar Publications